Dare Bioscience, Inc.

Welcome to the conference call hosted by DARE Bioscience to review the company's second quarter financial results and to provide a general business update. This call has been recorded. My name is Leonardo, and I will be your operator today. With us today from DARE are Sabina Martusi-Johnson, President and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting Officer. Ms. Herring-Layton, please proceed.

Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update call for the quarter ended June 30th, 2024. Today we will review our second quarter results and discuss developments and expectations for our pipeline and portfolio. I'd like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings including on form 10Q for the quarter ended June 30th, 2024, which was filed today. I would also like to point out that the content of this call includes time sensitive information that is current as of today, August 12th, 2024. SARA undertakes no obligation to update any forward looking statements to reflect new information or developments after this call, except as required by law. I will now turn it over to Sabrina.

Thank you. I always like to start our quarterly calls by taking a minute to remind those of you who may be newer to the DARE story of our purpose and our mission. We believe DARE is the only publicly traded company focused solely on women's health, pharmaceutical product development broadly, and we remain dedicated to advancing disruptive products for the health and well-being of women through clinical development, regulatory review, and ultimately to market. Our commitment and focus is to improve health outcomes and the lives of women by leveraging the basic science and pharmacology that is understood about certain active pharmaceutical ingredients and marketed products to accelerate innovative treatments that women want and need by boldly addressing existing therapeutic gaps. We seek to optimize these treatments for our target indications to enhance outcomes, convenience, and side effect profile, or to address a novel indication where the pharmacology is well-suited but has not previously been applied to the indication in question for women. We believe we have the broadest portfolio of potential high-impact, first-in-category product candidates to improve the health and well-being of women, many of which have already demonstrated proof of concept, and that our robust pipeline positions us well for the short, medium, and long term. During our last update call, we discussed the strides we made last year to advance innovative therapies for women and the key milestones anticipated for 2024. In addition to the continued commercialization of Zasciato Clindamycin Phosphate Vaginal Gel 2%, the first FDA approved product to emerge from our portfolio, and a treatment for bacterial vaginosis in females aged 12 and older that became available nationwide by prescription earlier this year via our collaborator, Organon. We also discussed anticipated milestones focused on our first in category product candidates related to continuing to progress toward a phase three trial of Sidenafil cream 3.6%, which has the potential to be the first FDA approved treatment for female sexual arousal disorder. for which there are no FDA-approved treatments, and continuing to enroll in our phase three study of oviprene, are potentially first in category hormone-free monthly intravaginal contraceptive candidates. Today, we'll review our progress against the anticipated milestones for oviprene and sildenafil cream with a focus on providing context and metrics that are important to understanding the potential impact of these programs. We'll also highlight today the status of and what comes next for our two product candidates in the menopause space, our monthly vaginal hormone therapy for hot flashes and our hormone-free vaginal insert for sexual pain. Before I do, I'm going to first turn the call back over to our Chief Accounting Officer, Marty, to review our second quarter financial results.